General Dermatology

Understanding urticaria subtypes, from spontaneous to inducible, is key to crafting patient-specific management plans.

According to a phase 3 study, the omalizumab biosimilar saw comparable results with a good safety profile.

In his presentation at Winter Clinical Miami, Del Rosso covered new and emerging therapies as well as successful off-label uses.

Attovia is also advancing 4 ATTOBODY-based programs for inflammatory conditions, such as atopic dermatitis and IBD.

Adam Friedman, MD, FAAD, takes a closer look at the emerging landscape of oral treatments for hyperhidrosis and what lies ahead in advancing patient care.

Jason Hawkes, MD, MS, discusses unmet needs in chronic urticaria care and challenges outdated testing practices.

Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.

Hawkes combines personal experience and clinical expertise to treat urticaria patients.

Explore the top headlines of the week including the growth of NPs and PAs in the field, clinical trial updates, and advancements in therapy.

In case you missed it, this week we had news about AIs and CNNs for early melanoma detection, OCT Technology for vitiligo imaging, UCB’s 320mg single-injection bimekizumab, and more.

A recent study evaluated the efficacy of low-energy delicate pulsed light photomodulation for treating sensitive skin, showing significant improvements in symptoms and erythema.

Mitragotri's work bridges advanced drug development and skin care for tailored treatments.

The new dosing option offers convenience for those managing plaque psoriasis, PsA, and hidradenitis suppurativa.

Soligenix recently shared interim results from a 12-month investigator-initiated study of synthetic hypericin.

A study found that UK adults living with psoriasis and vitiligo were better able to self-manage the psychological implications of their condition.

In case you missed it, this week we had news about phase 2b enrollment for VYNE’s vitiligo gel, the impact of anti-inflammatory moisturizers for AD, the newly FDA-approved DermiSphere hDRT, and more.

Explore the top headlines of the week including clinical trial updates, FDA announcements, and expert insights.

Advancements in therapeutic agents demand innovative strategies for safe, localized skin treatments, Mitragotri argues.

Mitragotri said new innovations like ionic liquid-based delivery systems can offer better treatment for immunodermatological conditions.

UVF dermoscopy enhances scabies detection, especially in dark skin, with optimal results when combined with polarized light examination.

The innovative technology is unlocking new possibilities in dermatology by improving the solubility and permeability of drugs for topical use.

Palvella begins its phase 2 TOIVA trial of Qtorin rapamycin gel for cutaneous venous malformations, targeting the mTOR pathway.

While zinc deficiency shows strong ties to SD, researchers stated vitamin D's role is less clear and may depend on genetic factors.

By addressing skin health proactively, runners can enhance performance and longevity in the sport while minimizing discomfort and long-term dermatological damage.

Share your insights and anticipation with us.

The FDA recently proposed a new rule requiring standardized asbestos testing in talc-containing cosmetics to protect consumers from potential harm.

In case you missed it, this week we had news about a significant dual treatment approach for AD, organic filter-based sunscreens for sensitive skin, what we’re most looking forward to in 2025, and more.

Explore the top headlines of the week including 2025 PDUFA dates, 2024 interview insights, and awareness dates to add to your calendar.

After 8 weeks of use, the product showed improvements in skin sensitivity, transepidermal water loss, and skin corneum hydration.

We're welcoming 2025 with dermatology innovations, expert insights on chronic hand eczema, and new leadership at Dermatology Times.